Tests a device that heats lung tumors through a bronchoscope before surgery
Studies a heating device used through a bronchoscope in adults with lung cancer.
Plain-language title generated from the registry record
Registry title: Bronchoscopic Microwave Ablation of Lung Tissue in Surgical Candidates
Key facts
- Where
- Amsterdam, NetherlandsSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with lung cancer confirmed by tissue testing. They must be able to have the nodule removed by surgery. The nodule is treated with microwave heat through a bronchoscope before surgery.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Lung nodule confirmed as cancer, not small cell lung cancer. Soft tissue nodule up to 30 mm (Stage A) or up to 20 mm (Stage B). More than 10 mm of tumour-free lung between the nodule and the pleura or fissure. A tumour board or team of doctors says surgery is possible.
- Earlier treatment
- No chemotherapy, immunosuppressive treatment or radiotherapy within 3 months of the study procedure. No earlier treatment such as SBRT in the same lung lobe as the target nodule. No earlier pneumonectomy.
Main reasons for not taking part
- Nodule in the central zone of the chest (bronchial tree, major vessels, heart, oesophagus, spinal cord, nerves)
- Pregnant or breast feeding
- Expected survival less than 12 months
- Pacemaker or other implanted electronic device
- Bleeding disorder, or blood thinners that cannot be stopped or paused
Read by machine on 12 November 2026.
Where in Netherlands
- Amsterdam University Medical Centres, Location AMC, Meibergdreef 9Amsterdam, NetherlandsContact: Saskia van Heumen, Technical PhysicianTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Creo Medical Limited
- Trial code
- NCT06689488
- Record updated
- 26 June 2026
- Original description
The overall purpose of this study is to characterise the clinical safety and performance of the Creo Medical MicroBlate™ Flex AB1 instrument in patients with pathologically confirmed malignancy eligible for surgical resection of their nodule, receiving bronchoscopic ablation prior to surgery.Read full original descriptionShow less
Assessment of the Safety and Performance of the AB1 Electrosurgical System for Bronchoscopic Microwave Ablation of Lung Tissue in Surgical Candidates
The overall purpose of this study is to characterise the clinical safety and performance of the Creo Medical MicroBlate™ Flex AB1 instrument in patients with pathologically confirmed malignancy eligible for surgical resection of their nodule, receiving bronchoscopic ablation prior to surgery.
Inclusion: Patients who:; Have signed informed consent; Subject is willing and able to comply with all aspects of the treatment and evaluation schedule; Are ≥ 18 years old; Have lung lesion(s)/nodule(s) which are histopathological-confirmed as cancer; Have soft tissue lung lesion(s):; ≤ 30 mm in the largest dimension of the pulmonary window for Stage A; ≤ 20 mm in the largest dimension of the pulmonary window for Stage B; Are candidates for surgical resection as determined by a multi-disciplinary team (MDT) or tumour board; Greater than 10 mm of tumour-free lung parenchyma between target tumour and pleura or fissure; Subject is willing and able to comply with the study protocol requirements; Are assigned an ASA (American Society of Anaesthesiologists) score of ≤ 3 or the patient is deemed fit for general anaesthesia.
Exclusion: Have participated in an investigational drug or device research study within 30 days of enrolment that would interfere with this study; Have an implantable device, including pacemakers or other electronic implants; Subject had a prior pneumonectomy; Subjects currently undergoing or underwent chemotherapy, systemic immunosuppressive treatment, or radiotherapy within 3 months of planned Study procedure; Have target nodule(s) within the International Association for the Study of Lung Cancer (IASLC) "Central Zone" (including bronchial tree, major vessels, heart, oesophagus, spinal cord, and phrenic \& laryngeal nerves); Have a physical or psychological condition that would impair study participation or jeopardise the safety or welfare of the subject; Have known pulmonary hypertension (PASP [pulmonary artery systolic pressure] >50mmHg); Diagnosis of Small Cell Lung Cancer; Any patient with clinically significant interstitial lung disease in the zone of planned ablation; Have bleeding diathesis, uncorrectable coagulopathy, or platelet count ≤ 100 x 10\^9/L; Who are currently prescribed anticoagulants, clopidogrel or other platelet aggregation inhibitors which can´t be stopped or temporarily withheld; Patients who:; Are pregnant or breast feeding, as determined by standard site practices; Have an expected survival less than 12 months; Subject had a therapeutic intervention (e.g., SBRT) within same lobe as the target lesion.